$85.650
-0.077 (-0.09%)At close
RMBS News
RMBS Events
Rambus and ChipAgents Sign Strategic Agreement to Accelerate Chip Design
Rambus and ChipAgents announced a multi-faceted strategic agreement to accelerate chip design with agentic AI. As part of the agreement, Rambus is adopting the ChipAgents platform companywide, including deployment across its chip and silicon IP design and verification workflows to accelerate the pace of development. The companies will also collaborate to leverage Rambus' deep semiconductor expertise and ChipAgents' agentic AI platform and agentic workflows to enable greater speed and Quality of Result in our customers' chip design process across their preferred design environments. In addition, Rambus has become a strategic investor in ChipAgents, reflecting its confidence in the growing role of AI-native engineering in the future of chip design.
Rambus Initiates $100M Accelerated Share Repurchase Program
Rambus initiated an accelerated share repurchase program with Mizuho Markets Americas, through its agent Mizuho Securities USA to repurchase an aggregate of approximately $100M of its common stock. Under the accelerated share repurchase program, Rambus will pre-pay $100M to Dealer and receive an initial delivery of approximately 796,000 shares of its common stock. The final number of shares to be repurchased will be determined based on the volume-weighted average price of Rambus common stock during the term of the transaction, less a discount. The program is expected to be completed by the end of the third quarter of 2026.
Rambus Reports Q2 Revenue of $207.4M
Reports Q2 reveenue $207.4M, consensus $198.3M. "Rambus had an outstanding second quarter, delivering a new all-time high in revenue and non-GAAP earnings, fueled by record product revenue that grew more than 20% year over year," said Luc Seraphin, president and chief executive officer of Rambus. "We continue to execute on our roadmap of high-performance chip and IP solutions to meet the accelerating demands of data center and AI infrastructure. We are well positioned to capitalize on the strong secular trends driven by the rapid expansion of AI inference and agentic workloads, supporting our continued product momentum and long-term profitable growth."
Sees Q3 Revenue of $210M-$216M
Sees Q3 revenue $210M-$216M, consensus $212.97M.
Micron Technology Shares Rise 14.4%, Boosting Semiconductor Sector
The tech sector remained under pressure on Wednesday as investors continued to flock to the safety of counter-cyclical areas of the market such as Utilities and Health Care. Energy lagged as continued signs of a Middle East de-escalation and progress in Strait of Hormuz reopening has pulled the price of WTI Crude Oil futures below $70 per barrel.The evening session and a blowout earnings report from Micronhas manifested a sea change in sentiment and the likelihood of a snap-back rally in the AI trade on Thursday. Shares of the memory maker were up over 14%, nearly erasing all of yesterday's broadbased losses. The strong results from Micron also put a bid under the other semiconductor and memory names. Elsewhere, a robust medium-term outlook from Qualcommwith a higher non-handset revenue target of $40B further relieved the tensions regarding valuations in Semis. Late in afterhours, S&P e-minis are up 10.6% and Nasdaq 100 contract is up 2.0%.Check out this evening's top movers from around Wall Street, compiled by The Fly.HIGHER AFTER EARNINGS -Micronup 14.4%; Other semis and memory names broadly up in sympathy: Lam Researchup 6.5%, Rambusup 6.8%, Arm Holdingsup 6.7%, Sandiskup 11.1%, Western Digitalup 10.9%.Methode Electronics, Inc.up 14.4%ALSO HIGHER -Qualcommup 12.9% after disclosing medium-term targetsNETSTREITup 5.8% after entering S&P SmallCap 600 indexFormFactor, Inc.up 5.2% after being added to Russell 1000 indexDOWN AFTER EARNINGS -MillerKnolldown 4.9%Trip.com Group Limiteddown 4.3%H.B. Fullerdown 1.9%Jefferiesdown 1.6%ALSO LOWER -ARS Pharmaceuticalsdown 23.8% after commercial update on neffyTaysha Gene Therapiesdown 7.8% after equity offeringCG Oncology, Inc.down 5.4% after block trade
This page is for research only and is not investment advice. Models can be wrong. Past performance does not guarantee future results.